Find-A-Study

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Purpose

To investigate the efficacy, safety and tolerability of BI 409306 once daily compared to placebo given for 52 weeks to subjects with attenuated psychosis syndrome.

Study Contact

Floyd Jones
+1 (210) 450-3158
jonesfa@uthscsa.edu

Amy Saklad
(210) 567-8229
saklada@uthscsa.edu

Mary Woolsey
(210) 567-8049
woolseym@uthscsa.edu

Principal Investigator
David Glahn

David Glahn
david.glahn@childrens.harvard.edu

Floyd Jones
+1 (210) 450-3158
jonesfa@uthscsa.edu

Amy Saklad
(210) 567-8229
saklada@uthscsa.edu

Mary Woolsey
(210) 567-8049
woolseym@uthscsa.edu

Eligibility

Eligible Ages: Between 16 Years and 30 Years
Eligible Genders: All
Accepts Healthy Volunteers: No

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Purpose

Category

Study Contact

Eligibility

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups